Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: A randomized double-blind study

Schizophrenia Research

Volumn 143, Issue 1, 2013, Pages 18-24

  Smith, Robert C ^a,j   Jin, Hua ^b,k   Li, Chunbo ^c   Bark, Nigel ^d,l   Shekhar, Anantha ^e   Dwivedi, Sauburah ^f   Mortiere, Catherine ^g   Lohr, James ^b,k   Hu, Qiaoyan ^h   Davis, John M ⁱ  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^e SHANGHAI MENTAL HEALTH CENTER   (China)

^f Bronx Psychiatric Center   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^h INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ SUNY DOWNSTATE MEDICAL CENTER   (United States)

^j Kirby Forensic Psychiatric Center   (United States)

^k NORTHWESTERN UNIVERSITY   (United States)

^l UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

more..

Author keywords

Cognition; Depression; Diabetes; Glucose metabolism; Pioglitazone; Schizophrenia

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; NEUROLEPTIC AGENT; PIOGLITAZONE; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHINA; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HEMATOCRIT; HUMAN; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN DEFICIENCY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; METABOLIC PARAMETERS; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; ANTISOCIAL PERSONALITY DISORDER; CASE-CONTROL STUDIES; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; LIPID METABOLISM; MALE; METABOLIC DISEASES; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; THIAZOLIDINEDIONES;

EID: 84871934676     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.10.023     Document Type: Article

References (19)

1. DeFronzo R., Abdul-Ghani M. Type 2 diabetes can be prevented with early pharmacological intervention. Diabetes Care 2011, 34:s202-s209.
2. DeFronzo R., Tripathy D., Schwenke D., Banerji M., Bray G., Buchanan T., Clement S., Henry R., Hodis H., Kitabchi A., Mack W., Mudaliar S., Ratner R., Williams K., Stentz F., Musi N., Reaven P. Pioglitazone for diabetes prevention in impaired glucose tolerance. N. Engl. J. Med. 2011, 364:1104-1115.
3. Edlinger M., Ebenbichler C., Rettenbacher M., Fleischhacker W.W. Treatment of antipsychotic-associated hyperglycemia with pioglitazone: a case series. J. Clin. Psychopharmacol. 2007, 27:403-404.
4. Elashoff J.D. nQuery Advisor: Version 3.0, User's Guide 1999, Statistical Solutions, Ltd.
5. Erdmann E., Charbonnel B., Wilcox R., Skene A., Massi-Benedetti M., Yates J., Tan M., Spanheimer R., Standl E., Dormandy J. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007, 30:2773-2778.
6. Erdmann E., Dormandy J., Charbonnel B., Massi-Benedetti M., Moules I., Skene A. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J. Am. Coll. Cardiol. 2007, 49:1772-1780.
7. Gold J.M., Queern C., Iannone V.N., Buchanan R.W. Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: sensitivity, reliability, and validity. Am. J. Psychiatry 1999, 156:1944-1950.
8. Kay S.R., Fizzbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
9. Kemp D., Ismail-Beigi F., Calabrese J. Antidepressant response associated with pioglitazone: support for an overlapping pathophysiology between major depression and metabolic syndrome. Am. J. Psychiatry 2009, 166:619-619.
10. Kemp E., Ismail-Beigi F., Ganocy S., Conroy C., Gao K., Obral S., Fein E., Findling R., Calabresse J. Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity. J. Affect. Disord. 2012, 136:1164-1173.
11. Knowler W., Barrett Connor E., Fowler S., Hamman R., Lachin J., Walker E., Nathan D. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002, 346:393-403.
12. Parker J. Troglitazone: the discovery and development of a novel therapy for treatment of type 2 diabetes mellitus. Adv. Drug Deliv. Rev. 2002, 54:1173-1197.
13. Pftzner A., Schneider C., Forst T. Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects. Expert. Rev. Cardiovasc. Ther. 2006, 4:445-459.
14. Psychological Corporation Vigil Continuous Performance Test 1988, Harcourt Brace and Company.
15. Ramachandran A., Snehalatha C., Mary S., Mukesh B., Bhaskar A.D., Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006, 49:289-297.
16. Sato T., Hirao K., Kanettaka H., Sakurai H., Iwamoto T. Efficacy of PPAR-gamma agonist pioglitazone in mild alzheimer disease. Neurobiol. Aging 2011, 32:1626-1633.
17. Smith R., Lindenmayer J., Davis J., Kelly E., Viviano T., Cornwell J., Hu Q., Khan A., Vaidhyanathaswamy S. Effects of olanzapine and risperidone on glucose metabolism and Insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study. J. Clin. Psychiatry 2009, 70:1501-1513.
18. Smith R., Lindenmayer J.-P., Hu Q., Kelly E., Viviano T., Cornwell J., Vaidhyanathaswamy S., Marcovina S., Davis J. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study. Schizophr. Res. 2010, 120:204-209.
19. Stumvoll M., Herring H. Glitazones: clinical effects and molecular mechanisms. Ann. Med. 2002, 34:217-224.